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1. Introduction 
Severe sepsis and septic shock are major concerns within our health care system, accounting 
for 2.26 cases per 100 hospital discharges (Angus et al., 2001). The incidence of sepsis has 
increased by 9% each year (Martin et al., 2003), and mortality ranges from 17.9% to 70% 
depending on severity of disease and factors such as age, sex, ethnic origin, and 
comorbidities (Angus et al., 2001; Martin et al., 2003; Alberti et al., 2002). The annual 
economic burden of severe sepsis in the United States is $17 billion (Angus et al., 2001).  
Early goal-directed therapy is a stepwise approach to treatment of severe sepsis and septic 
shock and includes fluid resuscitation, optimizing hemodynamic parameters, early and 
appropriate antibiotic administration, and source identification and control (Figure 1). The 
appropriate use of EGDT has shown to significantly reduce mortality, demonstrating an 
absolute risk reduction in mortality of 16% compared to physician-driven treatment (Rivers 
et al., 2001). Beyond these recommendations, there are several adjunctive therapies which  
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Adapted from the Surviving Sepsis Campaign guidelines for management of severe sepsis and septic 
shock (Dellinger et al., 2008). 
Fig. 1. Early Goal-Directed Therapy. 
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have been studied; their use, however, is highly dependent upon severity of illness, 
response to EGTD, and patient-specific characteristics. The use of these adjunctive therapies 
is also limited by their evidence in the literature compared to other approaches such as fluid 
resuscitation and early and appropriate antibiotic administration. 
The goal of this chapter is to discuss alternative pharmacologic therapies for the treatment of 
septic shock following the initiation and optimization of EGDT. The therapies discussed in 
this chapter are as follows: corticosteroids, activated protein C, immunoglobulin, statins, 
and toll-like receptor inhibitors. 
2. Pathophysiology of sepsis 
The rationale for use of targeted therapies in sepsis is based on pathophysiologic processes. 
As discussed in other chapters, sepsis results from the complex interaction between an 
infecting pathogen and host responses, including inflammation, coagulation and the 
immune system (Russel, 2006).  The immune system, which consists of mucosal defences to 
prevent host tissue invasion, is comprised of endogenous bacterial flora and structural 
barriers, an early response mounted by the innate immune system, and a delayed response 
via the adaptive immune system (Nduka & Parrillo, 2009). The key concept in the 
development and progression from infection to sepsis to severe sepsis and septic shock is 
the disparity between the host response and the invading organism’s virulence.  
3. Corticosteroids 
3.1 Mechanism of action 
Adrenal insufficiency is a common finding in patients with severe sepsis and septic shock 
(Annetta et al., 2009).  Previous literature has demonstrated that elevated baseline cortisol 
levels or inadequate response to stimulation via a corticotropin test are associated with 
higher mortality (Annane et al., 2000). 
Secretion of cortisol is controlled by the hypothalamic-pituitary-adrenal (HPA) axis and 
stimulated by fevers, pain, hypoxia, hypoglycemia and alterations in blood pressure. 
Stimulation of the HPA axis causes the hypothalamus to release corticotropin-releasing 
hormone (CRH), which in turn stimulates the pituitary to release adrenocorticotropic 
hormone (ACTH) (Figure 2) (Schimmer & Funder, 2011). Release of ACTH causes the zona 
fasciculata of the adrenal cortex to release glucocorticoids, primarily cortisol. Cortisol then 
inhibits further release of CRH and ACTH via a negative feedback mechanism (Annetta  
et al., 2009). 
Glucocorticoids have various effects on the body, mediating cardiovascular, metabolic, 
immunologic and inflammatory systems. Glucocorticoids are required for normal reactivity 
to α-mediated endogenous catecholamines (i.e norepinephrine, epinephrine) and 
angiotensin II (Chrousos, 2009). Not only do they stimulate the production of 
catecholamines, but they potentiate their actions through up-regulation of α-adrenergic 
receptors. Glucocorticoids also lead to inhibition of nitric oxide and prostaglandin synthesis, 
resulting in modulation of vascular permeability (Annetta et al., 2009; Marik et al., 2008). 
Metabolic effects of glucocorticoids include stimulation of gluconeogenesis and 
glycogenolysis resulting in increased blood glucose concentrations. Glucocorticoids activate 
proteinolysis in muscle and inhibit protein synthesis, resulting in increased free amino acid 
substrate for gluconeogenesis. Hyperglycemia is beneficial in stressful states such as sepsis 
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due to increased energy requirements (Pilkis & Granner, 1992).  Glucocorticoids inhibit 
osteoblasts and activate osteoclasts, resulting in bone destruction. They also decrease 
calcium stores through inhibition of intestinal calcium uptake and increased urinary 
secretion by decreasing renal reabsorption (Annetta et al., 2009). Glucocorticoids have potent 
anti-inflammatory and immune-modulating effects. They decrease the amount and function 
of several immune cells, including T and B lymphocytes, macrophages, neutrophils, 
eosinophils, and monocytes. They also modulate the activity and production of cytokines 
[i.e interleukin-1 (IL-1), IL-2, IL-6 and tumor necrosis factor alpha (TNF-α)], chemokines and 
other inflammatory mediators, such as histamine and bradykinin. Lastly, glucocorticoids 
have anti-inflammatory effects via propagation of the release of anti-inflammatory factors 
(IL-10, IL-1 receptor antagonist and soluble TNF receptor) (Annetta et al., 2009; Marik et al., 
2008; Fahey & Guyre, 1981). 
Severe illness and stress activate the HPA axis. Once activated, serum levels of cortisol-
binding globulin levels fall up to 50%, resulting in a significant increase in the amount of 
free cortisol (Ho et al., 2006). In critically ill patients this pathway may be impaired, 
resulting in adrenal insufficiency. Prevalence of adrenal insufficiency in septic shock has 
been reported in up to 60% of patients (Annane et al., 2006). The mechanism of action of 
HPA axis dysfunction is poorly-understood, but may include decreased production of  
CRH, ACTH, cortisol, and the dysfunction of their receptors.  Accord to the American 
College of Critical Care Medicine guidelines, HPA axis dysfunction in the setting of critical 
illness is best-described as critical illness-related corticosteroid insufficiency (CIRCI) (Marik 
et al., 2008).  
3.2 Pharmacology 
Many synthetic corticosteroids (e.g. dexamethasone, prednisone, etc.) have been developed 
to address pharmacological and therapeutic concerns, such as bioavailability and variable 
glucocorticoid and mineralocorticoid potencies (See Table 1). These agents are primarily 
used for their anti-inflammatory effects in disorders of various organ systems 
(Hydrocortisone prescribing information, 2010; Chrousos, 2008). 
Hydrocortisone is the pharmaceutical product equivalent to cortisol; therefore, it is used as 
replacement therapy in adrenocortical deficiency states (Hydrocortisone prescribing 
information, 2010; Chrousos, 2008).  
Hydrocortisone is available intravenously as the highly water-soluble hydrocortisone sodium 
succinate, which permits the immediate intravenous or intramuscular administration of high 
doses of hydrocortisone in a small volume of diluent.  Following the intravenous injection of 
hydrocortisone sodium succinate, demonstrable effects are evident within one hour and 
persist for a variable period. Hydrocortisone is primarily bound to corticosteroid-binding 
globulin.  Only 5% to 10% is unbound and biologically active. It is metabolized in the liver to 
inactive metabolites. Renal excretion of the administered dose is nearly complete within 12 
hours (Hydrocortisone prescribing information, 2010; Schimmer, 2011).  
Fludrocortisone is a synthetic corticosteroid with both glucocorticoid and mineralocorticoid 
activity; however, it has a much higher mineralocorticoid potency, producing marked 
sodium retention and increased urinary potassium excretion (Fludrocortisone prescribing 
information, 2009; Chrousos, 2008). 
Following oral administration, 100% of fludrocortisone is detected in the serum, half of 
which is bound to plasma proteins. It is metabolized in the liver and excreted renally with a 
half-life of 3.5 hours (Fludrocortisone prescribing information, 2009). 
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CRH=corticotropin releasing hormone, ACTH=adrenocorticotropin hormone 
Fig. 2. Corticosteroid mechanism of action. 
 
Relative potency to 
Hydrocortisone
Pharmacokinetics
Equivalent 
Glucocorticoid
Dose (mg)
Glucocorticoid Mineralocorticoid
Plasma half-life 
(minutes)
Duration of 
Action (hours)
Short Acting
Hydrocortisone 
(Cortisol)
20 1 1 90 8-12
Intermediate Acting
Prednisone 5 4 0.8 60 12-36
Prednisolone 5 4 0.8 200 12-36
Methylprednisolon
e
4 5 0.5 180 12-36
Long Acting
Dexamethasone 0.75 30 0 200 36-54
Mineralocorticoid
Fludrocortisone 0 15 150 240 24-36
Aldosterone 0 0 400+ 20 --
Reference: Adrenal Cortical Steroids. Drug Facts and Comparisons. 5th ed. St. Louis, Facts and Comparisons, Inc.:122-128, 1997
 
Table 1. Corticosteroid Dosing and Equivalence 
-
-
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3.3 Clinical trials 
Several clinical trials have been conducted assessing the use of steroid therapy in sepsis.  
In the last decade, four meta-analyses have been conducted to evaluate the benefit of 
corticosteroids in sepsis. The first two meta-analyses demonstrated high-dose corticosteroid 
use in sepsis and septic shock did not improve survival rates. (Cronin et al., 1995; Lefering & 
Neugebauer, 1995). The next two demonstrated long courses of low-dose corticosteroids to aid 
in earlier reversal of shock as well as a mortality benefit (Annane et al., 2004; Minneci et  
al., 2004). 
The first landmark trial in recent years assessing the use of corticosteroids in septic shock was 
a randomized, placebo-controlled, double-blind, multicenter study assessing hydrocortisone 
50 mg intravenous every 6 hours and fludrocortisone 50 µg by mouth daily for 7 days versus 
placebo in 300 patients with vasopressor-unresponsive septic shock (Annane et al., 2002).  
This study demonstrated significant shock reversal and a reduction in mortality in patients 
with relative adrenal insufficiency (non-responders to a corticotropin test). Adverse  
effects were similar between the two groups. The authors concluded that treatment with low 
doses of hydrocortisone and fludrocortisone significantly reduced the risk of death in patients 
with septic shock and relative adrenal insufficiency without increasing adverse events 
(Annane et al., 2002). 
The second clinical trial in recent years (the CORTICUS trial)  was a randomized, placebo-
controlled, double-blind, multicenter study assessing 251 patients that received hydrocortisone 
50 mg intravenous every 6 hours for 5 days versus 248 patients that received placebo (Sprung 
et al., 2008). This study failed to show a mortality benefit with steroid therapy for patients in 
septic shock with relative adrenal insufficiency (non-responders to a corticotropin test).  In the 
hydrocortisone group, shock was reversed earlier than in the placebo group; however, there 
were more episodes of superinfection, including new sepsis and septic shock.  (Sprung et al., 
2008). The external validity of this trial may be limited due to the inclusion of patients, 
regardless of their blood pressure response to vasopressors. This is an issue as patients with 
patients with blood pressures responsive to vasopressor therapy would likely not be 
candidates for steroid therapy. 
3.4 Place in therapy 
Based on the results of the aforementioned studies, there is much discord in regards to the 
optimal time to initiate corticosteroids for septic shock. Corticosteroids appear to reverse 
shock more rapidly, but effects on mortality are unclear and many adverse effects have been 
reported. Consensus guidelines suggest that intravenous hydrocortisone (200-300 mg daily 
in divided doses) be given only to adult septic shock patients unresponsive to fluid 
resuscitation and vasopressor therapy. The addition of oral fludrocortisone (50 µg daily) to 
corticosteroid therapy is considered optional if hydrocortisone is used (Dellinger et al., 2008; 
Marik et al., 2008). 
3.5 Adverse effects 
Complications associated with the use of corticosteroids are dependent upon dosage and 
duration of therapy. In critically ill patients, the most important adverse effects include 
immune suppression with an increased risk of infections (both typical and opportunistic), 
impaired wound healing, hyperglycemia, myopathies, hypokalemia, psychosis, HPA axis 
and GR suppression (Annetta et al., 2009). 
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4. Activated protein C 
4.1 Mechanism of action 
In sepsis, toxins and inflammatory cytokines (i.e. TNF-α and IL-1) cause direct activation of 
coagulation via up-regulation of tissue factor (TF) from monocytes and endothelial cells 
(Figure 3) (Bernard et al., 2001). TF leads to thrombin formation and fibrin clot. In addition 
inflammatory cytokines and thrombin can impair the endogenous fibrinolysis by stimulating 
the release of plasminogen-activator inhibitor 1 (PAI-1) from platelets and endothelial cells. 
PAI-1 is a potent inhibitor of tissue plasminogen activator, which lyses clots. Thrombin further 
potentiates the prothrombotic state when it activates thrombin-activatable fibrinolysis 
inhibitor (TAFI) (Toussaint & Gerlach, 2009; Dellinger, 2003; Bernard et al., 2001).  
 
Inflammatory FibrinolyticThrombotic
INFECTION 
or 
ENDOTOXIN
Monocytes
Endothelium
TNF-α
IL-1
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factor
Tissue 
factor
Factor VIIIa
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Thrombin
Fibrin Fibrin clot
PAI-1
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TAFI
2
2
3
1
Neutrophils 4
Actions of activated protein C: 1, Inhibit the production of inflammatory cytokines (TNF-α, IL-1, IL-
6); 2, inactivation of factors VIIIa and Va, limiting the production of thrombin; therefore, TAFI’s actions 
are also prevented; 3, inhibition of PAI-1; 4, reduce rolling of neutrophils and monocytes on injured 
endothelium by binding selectins. 
TNF-α=tumor necrosis factor alpha, IL-1=interleukin 1, IL-6=interleukin 6, TAFI=thrombin-
activatable fibrinolysis inhibitor, PAI-1=plasminogen-activator inhibitor 1  
Fig. 3. Mechanisms of action of Activated Protein C  
Protein C is activated when thrombin binds to thrombomodulin, which is impaired by  
the inflammatory response. Endothelial injury and pro-inflammatory cytokines decrease 
thrombomodulin levels resulting in activation of the coagulation cascade (Bernard et  
al., 2001). Coagulation in sepsis can lead to microvascular thrombosis, organ ischemia, 
multiorgan dysfunction, and death. Activated protein C is an anticoagulant and  
pro-fibrinolytic that exerts its effect through inactivation of clotting factors Va, VIIIa,  
and PAI-1, limiting the production of thrombin. A reduction in thrombin results in 
decreased activation of the coagulation cascade and also modulation of the systemic 
inflammatory response associated with sepsis (Toussaint & Gerlach, 2009; Dellinger, 2003; 
Bernard et al., 2001). 
4.2 Pharmacology 
Activated protein C is available pharmacologically as drotrecogin alfa. Following 
continuous intravenous administration of drotrecogin alfa at doses between 12 
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µg/kilograms (kg)/hour (hr) to 30 µg/kg/hr, steady state concentrations are reached within 
two hours. Drotrecogin alfa and endogenous activated protein C are inactivated  
by endogenous plasma protease inhibitors; therefore, no dosing adjustments are  
necessary for renal or hepatic dysfunction. The initial phase has a half-life of 13  
minutes and the second phase half-life is 1.6 hours (Drotrecogin alpha prescribing 
information, 2008).  
4.3 Clinical trials 
Two major clinical trials have explored the mortality benefit of drotrecogin alfa in patients 
with severe sepsis and septic shock. The first, the PROWESS study, was a randomized, 
double-blind, placebo-controlled, multicenter trial that enrolled 1690 patients with 
systemic inflammation and organ failure due to acute infection (Bernard et al., 2001). 
Patients received an intravenous infusion of either placebo or drotrecogin alfa at 24 
μg/kg/hr for 96 hours. This study was terminated early due to an absolute reduction in 
mortality of 6.1% in the treatment group (P=0.005). The incidence of serious bleeding was 
significantly higher in the drotrecogin alfa group than in the placebo group. A limitation 
of this study is the inclusion of prospectively-defined subgroup analyses performed for 
various baseline characteristics [i.e Acute Physiology and Chronic Health Evaluation 
(APACHE II) score, age, sex, protein C deficiency].  Although the authors stated there 
were consistent treatment effects between these groups, this may be misleading as 
subgroup analyses, in general, lack an intent to treat group as well as have the potential 
for sampling bias and sample error.   
In the recently –completed PROWESS-SHOCK trial, drotrecogin alpha failed to demonstrate 
a survival benefit. Preliminary analysis showed a 28-day all cause mortality rate of 26.4%  
in drotrecogin alpha group compared to 24.2% in placebo-treated patients (P=0.31). As a 
result, the manufacturer has announced a worldwide voluntary market withdrawal of 
drotrecogin alpha. 
4.4 Place in therapy 
Based on the results of the PROWESS trial, the Food and Drug Administration (FDA) 
approved drotrecogin alfa, but required a second study be conducted to evaluate its efficacy 
in patients with severe sepsis with a low risk of death. The ADDRESS study enrolled 2640 
patients with severe sepsis and an APACHE II score <25 or single organ failure to receive 
the same intervention as above (Abraham et al., 2005).  This trial was terminated early due 
to an increased risk of bleeding with no significant reduction in 28-day mortality (Abraham 
et al., 2005).  
4.5 Adverse effects 
As observed in clinical trials, bleeding is the significant adverse effect associated with 
administration of activated protein C (Bernard et al., 2001; Abraham et al., 2005). 
5. Immunoglobulin 
5.1 Mechanism of action 
Intravenous immunoglobulin G (IVIG) contains IgG antibodies produced by B 
lymphocyte cells pooled from several thousands of blood donors. IVIG generates high 
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polyspecificity against bacterial, viral, parasitic and mycoplasma antigens and their 
toxins. It has been shown to be efficacious in various autoimmune and immunodeficiency 
diseases (Norrby-Teglund & Stevens, 1998). There are four subclasses of IgG (IgG1, IgG2, 
IgG3, and IgG4), of which IgG1 is the major component in IVIG preparations. IgA and 
IgM are also found in preparations of immunoglobulin; however quantities are minuscule 
compared to IgG.  IgG1 has several functions within the immune system, including 
complement activation, tissue protection and virus inactivation. IgG1 also opsonizes 
bacteria, marking these cells for ingestion and phagocytosis (Knapp & Colburn, 1990).  
Superantigens are a class of antigens that cause non-specific activation of T-cells, resulting in 
massive cytokine release. Patients infected with these antigens develop severe and rapidly-
progressing sepsis (Ryan & Ray, 2010).  Due to its ability to neutralize a broad range of 
superantigens and facilitate opsonization of streptococci (Norrby-Teglund & Stevens, 1998), 
IVIG therapy has been implicated in the treatment of septic shock secondary to group A 
Streptococci (GAS) infections, including necrotizing fasciitis and streptococcal toxic shock 
syndrome (STSS) (Darenberg et al., 2003). Both of these manifestations of GAS are severe, 
invasive infections with mortality rates up to 80% despite early and appropriate 
antimicrobial therapy (Davies et al., 1996).  
5.2 Pharmacology 
Immunoglobulin is available in subcutaneous and intravenous formulations. The 
bioavailability of subcutaneous immunoglobulin is approximately 73% compared to IVIG.  
After administration of IVIG (0.1–2 g/kg), serum concentrations rise, then fall rapidly in the 
first 1 to 7 days due to diffusion into lymph and extracellular fluid compartments 
(Immunoglobulin prescribing information, 2010). IVIG catabolism occurs slowly thereafter. 
The half-life of IgG is dependent on the half-lives of the IgG subclasses (Knapp & Colburn, 
1990). There are several commercial preparations of IVIG available that contain varying 
amounts of IgG subclasses. Therefore, the half-life is dependent upon the product used, 
which report half-lives ranging between 25-48 days (Bonilla, 2008).  
5.3 Clinical trials 
There is a preponderance of literature available on the use of IVIG for treatment of severe 
sepsis and septic shock. However, many of these studies are observational in nature and 
limited in the number of participants and statistical power.  
In order to assess the overall mortality benefit of IVIG therapy in severe sepsis and septic 
shock, a meta-analysis of 14 randomized controlled trials between 1988 and 2006 was 
conducted (Laupland et al., 2007). Most of these studies were small, ranging from 21 to 653 
participants, comprised primarily of surgical intensive care unit patients with gram-negative 
infections. The median dose of IVIG was 0.92g/kg, with an interquartile range (IQR) from 
0.75 to 1.0 g/kg, and half of the studies used preparations of IVIG that where enriched with 
IgA and/or IgM. Overall, there was a significant mortality benefit associated with use of 
IVIG in adults with sepsis. However, this effect was lost when only the high-quality studies 
where included in the analysis. High quality studies were considered those with adequate 
blinding, allocation concealment, and those that used intention-to-treat analysis. The 
authors concluded that further research is needed to determine the mortality benefit of IVIG 
in severe sepsis and septic shock (Laupland et al., 2007). 
One study included in the above meta-analysis focused specifically on patients with STSS. This 
was a randomized, placebo-controlled, double-blind, multicenter study of 21 patients, of 
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whom 10 received IVIG and 11 received placebo (Darenberg et al., 2003). This study was 
terminated prematurely due to slow patient recruitment, which was thought to be secondary 
to a low incidence of STSS in the participating centers. A dose of 1 g/kg on day 1 and 0.5 g/kg 
on days 2 and 3 was used. Though not statistically significant, the primary endpoint of 
mortality at 28 days was found to be 3.6-fold higher in placebo group (1 patient, IVIG vs. 4 
patients, placebo). Patients in the treatment group also had a significant decrease in the sepsis-
related organ failure assessment (SOFA) score at days 2 and 3. This study is limited by the 
number of patients enrolled; however it demonstrates that further research should be 
conducted to determine the benefit of IVIG therapy in STSS. 
5.4 Place in therapy 
The sepsis guidelines recommend that IVIG be used in children with sepsis and septic 
shock; however, there are no formal recommendation for the use of IVIG in adults.  
(Dellinger et al., 2008) The aforementioned meta-analysis demonstrated a mortality benefit 
with IVIG therapy as an adjuvant to standard of care.  However, at this time further research 
is needed to determine which patients would benefit most from IVIG therapy.  Though high 
quality studies are limited, there may be a mortality benefit in using IVIG in patients with 
STSS. The theoretical benefit of IVIG in septic patients infected with superantigen-
generating pathogens is supported by one small study; however, larger, well-designed 
studies are needed.  At present IVIG should be considered in patients with rapidly 
progressing sepsis due to confirmed or suspected GAS. 
5.5 Adverse effects 
The most common adverse reactions observed in ≥5% of the patients were headache, 
pyrexia, fatigue, rigors, nausea, chills, dizziness, vomiting, migraines, pain in extremities, 
urticaria, and cough. Hypersensitivity reactions have also been observed, so epinephrine 
should be readily available when administering.  IVIG can induce a severe fall in blood 
pressure with anaphylactic reaction, even in patients who have tolerated previous treatment 
with IVIG (Immunoglobulin prescribing information, 2010). 
Caution should be used in patients with acute or chronic renal failure, as over 100 cases of 
renal failure associated with IVIG have been reported.  Patients predisposed to acute renal 
failure include those with any degree of preexisting renal insufficiency, diabetes mellitus, 
age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known 
nephrotoxic drugs. Especially in such patients, IGIV products should be administered at the 
minimum concentration available and the minimum rate of infusion feasible (Bonilla et al., 
2008; Immunoglobulin prescribing information, 2010).  
Aseptic meningitis has also been associated with IVIG use.  There appears to be an increased 
risk of aseptic meningitis in patients with a history of migraines.  Possible inciting factors 
include the IgG itself, various stabilizing products within each of the preparations, cytokine 
release triggered by the therapy, or cerebrovascular sensitivity (Sekul et al., 1994).  
6. Statins 
6.1 Mechanism of action 
Statins are a class of lipid-lowering agents which inhibit the enzyme 3-hydroxyl-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase. Traditionally, they have been indicated 
for primary and secondary prevention of cardiovascular disease due their effects on 
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reducing atherosclerosis.  Endogenous cholesterol production starts from the precursor 
acetyl-CoA, which then is converted to hydroxymethylglutaryl-CoA (HMG-CoA). HMG-
CoA reductase catalyzes the conversion of HMG-CoA to mevalonate in the rate-limiting 
step of cholesterol synthesis.  Mevalonate is then converted to cholesterol through several 
steps. Inhibition of HMG-CoA reductase has been shown to reduce total cholesterol, low-
density lipoprotein (LDL) cholesterol, apolipoprotein B, triglycerides, and increase high-
density lipoprotein (HDL) cholesterol (Goa et al., 2008; Terblanche et al., 2006).  
Independent from their lipid-lowering effects, statins exert various pleiotropic effects. They 
play a role in immune modulation, resulting in attenuation of the immune response. In 
animal models, statins have been shown to reduce leukocyte recruitment, adherence, and 
transmigration in a time-dependent manner (Goa et al., 2008; Diomede et al., 2001). Statins 
also cause a significant reduction of leucocytes adhesion to endothelium by down-
regulation endothelial cell adhesion molecules on the cell surface (Goa et al., 2008; Pruefer et 
al., 2002). Finally, statins affect monocyte function. In a double-blind, placebo-controlled 
study of 20 healthy male volunteers, simvastatin was shown to attenuate up-regulation of 
toll-like receptors (TLR) 2 and 4 on the surface of monocytes by more than half after a 
lipopolysaccharide challenge. Blocking TLR expression was associated with decreased 
concentrations immune cytokines, such as TNF-a and monocyte chemoattractant protein-1 
(Goa et al., 2008; Niessner et al., 2006).  
Statins also inhibit pro-inflammatory markers, decreasing response to activation of the 
inflammatory cascade. In animal studies, statins were shown to reduce exudate production 
of interleukin-6 (IL-6) and monocyte chemotactic proteins (Diomede et al., 2001), as well as 
TNF-a, IL-8 and other inflammatory mediators involved in sepsis (Grip et al., 2002).  Statins, 
particularly atorvastatin (Goa et al., 2008), have been shown to reduce serum concentrations 
of C-reactive protein (CRP), which is a major acute phase reactant in humans. CRP is 
produced mainly in the liver in response to IL-6. Statins decrease IL-6-induced CRP 
production through inhibition of protein geranylgeranylation within the hepatocytes 
(Arnaud et al., 2005).  
Statins also modulate the coagulation cascade. They reduce monocyte tissue factor (TF) 
expression, decrease concentrations of von Willebrand factor, increase the expression and 
functional activity of thrombomodulin which in turn binds to thrombin to activate protein 
C, reduce levels of plasminogen activator inhibitor-1 (PAI-1) and increase tissue-type 
plasminogen activator (tPA), and reduce platelet aggregation, and reduce conversion of 
prothrombin to thrombin leading to a decrease in levels of fibrinogen. (Goa et al., 2008; 
Steiner et al.,2005; Bickel et al., 2002; Terblanche et al., 2006; Shi et al., 2003; Bourcier & 
Libby, 2000). 
Endothelial cell dysfunction is central to the development of sepsis. Statins prevent this by 
increasing expression of endothelial nitric oxide synthase (eNOS), in conjunction with 
down-regulation of inducible nitric oxide synthase (iNOS). eNOS is activated to produce 
endothelium-derived NO for controlling vasomotor activity. This decreases occurrence of 
hypotension and attenuates resistance to vasoactive agents in patients with septic shock 
(Goa et al., 2008; McGown & Brookes, 2007).  
6.2 Pharmacology 
There are six different pharmacologic preparations of statins, each with varying dosing and 
relative potency (Table 2) (Goa et al., 2008; Pharmacist’s Letter, 2009). Lovastatin, pravastatin 
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sodium, and simvastatin are fungal-derived agents, whereas atorvastatin calcium, fluvastatin 
sodium and rosuvastatin are fully synthetic compounds (Goa et al., 2008). Statins are only 
available orally; therefore these agents cannot be administered to patients that do not have oral 
or enteral access for medication administration. Following absorption, statins undergo 
extensive first-pass extraction in the liver, thus the availability of drug in systemic circulation is 
variable. Most of the agents are metabolized in the liver through the cytochrome P450 (CYP 
450) system; therefore, careful examination for drug interactions is warranted. Pravastatin is 
metabolized hepatically via sulfation; therefore, it may be considered over other agents for 
patients on concomitant substrates or inhibitors of CYP3A4 or CYP2C9.  Statins have variable 
renal elimination. (Goa et al., 2008; Simvastatin prescribing information, 2011; Lovastatin 
prescribing information, 2010; Pravastain prescribing information, 2011).   
 
Statins*
Drug Dose 
(mg)
Equivalent 
Dose (mg)
Bioavailability 
(%)
Protein 
Binding (%)
Metabolism Half-life (hr)
Atorvastatin 10-80 20 12 98 CYP3A4 13-16
Fluvastatin 20-80 -- 24 98 CYP2C9 1-3
Lovastatin 20-80 80 5 >95 CYP3A4 2-3
Pitavastain 1-4 -- 80 96 UGT1A3,
UGT2B7
11
Pravastatin 10-40 80 20 43-67 sulfation 2-3
Rosuvastatin 10-40 5 20 90 CYP2C9 19
Simvastain 10-80** 40 5 95-98 CYP3A4 1-3
* Goa,2008; Pharmacist’s Letter, 2009
**Simvastain 80 mg is no longer recommended by the FDA unless previously maintained on this dose of > 1 year  
Table 2. Statin Dosing and Equivalence 
Though statins undergo hepatic metabolism, patients with renal dysfunction should exercise 
caution when using statins. They are also contraindicated in patients with active liver 
disease, including unexplained persistent elevations in hepatic transaminases (Simvastatin 
prescribing information, 2011). 
All statins are pregnancy category X, meaning that they are contraindicated in women who 
are or may become pregnant. Cholesterol and cholesterol derivatives are needed for normal 
fetal development, and congenital abnormalities have been reported (Simvastatin 
prescribing information, 2011). 
6.3 Clinical trials 
There is much literature demonstrating the lipid-lowering properties of statins, but 
randomized, controlled trials examining their pleiotropic effects for treatment of severe 
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sepsis and septic shock are limited. Several retrospective and prospective observational 
studies have been conducting to explore infection-related mortality and incidence of 
hospitalization from sepsis in patients receiving statins. These studies have yielded mixed 
results (Almog et al., 2007; Gupta et al., 2007; Majumdar et al., 2006).  
In order to clarify the effects of statin use in patients with sepsis, a recent meta-analysis was 
conducted. Twenty studies were included in the analysis, of which 18 were cohort studies, 1 
matched cohort study with 2 case-control studies, and 1 randomized control trial (Janda et 
al., 2010). Meta-analysis for various infection-related outcomes favored use of statins for 30-
day mortality, in-hospital mortality, pneumonia-related mortality, bacteremia-related 
mortality, sepsis-related mortality, and mixed infection-related mortality. The analysis was 
limited by the cohort design of the selected studies and the degree of heterogeneity among 
them, necessitating further randomized controlled studies (Janda et al., 2010).  
One prospective, randomized, double-blind, placebo-controlled trial of 150 patients on 
preexisting statin therapy requiring hospitalization for infection compared atorvastatin 20 
milligrams (mg) to placebo ((Kruger et al., 2011). No difference was found in progression of 
sepsis during hospitalization. The rate of decline of severe sepsis was similar between the 
groups. There was also no difference in mortality between the two groups; however, most of 
the study patients were not critically ill. Investigators concluded that this study does not 
support a beneficial role of continuing pre-existing statin therapy in patients with sepsis.  
Cessation of statin therapy was not associated with adverse effects secondary to rebound 
inflammation (Kruger et al., 2011). 
6.4 Place in therapy 
Currently sepsis consensus guidelines make no mention of statins as an adjunctive therapy 
for treatment of severe sepsis and septic shock. Conflicting data precludes a definitive 
recommendation for continuing pre-existing statin therapy in patients admitted with severe 
sepsis or septic shock. In patients with patent oral or parenteral access for medications, 
continuing statin therapy may be considered.   
6.5 Adverse effects 
Statins are safe in the majority of patients receiving them; however, in recent years attention 
has been drawn to their ability to cause myopathies progressing to rhabodomyolysis and 
liver dysfunction. These adverse effects are of particular concern in patients that develop 
sepsis because liver failure is a common complication of sepsis and drugs used in treating 
sepsis, such as steroids and neuromuscular blocking agents, can also cause myopathies (Goa 
et al., 2008; Pasternak et al., 2002).    
Elevated liver transaminases occur in 0.5 to 2% of patients taking statins and are dose-
dependent; however, progression to liver failure due to statins is very rare. Reversal of 
elevated transaminases frequently occurs with reduction in dose, and elevations do not 
often recur with either re-challenge or selection of another statin. Cholestasis and active liver 
disease are contraindications to statin use, but exacerbation of liver disease by statins has 
not been shown (Pasternak et al., 2002).    
Myopathies are characterized by non-specific muscle aches or joint pain, usually without 
elevations in creatinine kinase (CK). Rarely, patients on statins may develop muscle aches 
and pains associated with elevated CK, generally >10 times the upper limit of normal 
(ULN).  Failure to discontinue statin therapy can lead to rhabdomyolysis, myoglobinuria, 
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and acute renal necrosis. In 2001, cerivastatin was withdrawn from the market due to 
reports of serious myopathy, including 31 reports of death from rhabdomyolysis in the 
United States (Pasternak et al., 2002). More recently, the Food and Drug Administration 
(FDA) has put out a recommendation to limit the use of simvastain 80 mg due to risk of 
muscle injury (FDA Consumer Health Information, 2011).  
In 2002, the American College of Cardiology/American Heart Association/National Heart, 
Lung and Blood Institute issued a clinical advisory on the use and safety of statins. It 
recommends that all patients initiated on a statin should have liver transaminases checked 
after 12 weeks of therapy, then annually. CK should be monitored at baseline, and then 
muscle symptoms should be evaluated 6 to 12 weeks after initiation. If symptoms are 
present, a CK should be obtained. This statement also highlighted patients at risk for 
developing myopathies, including patients >80 years, small body frame and frailty, 
multisystem disease, multiple medications, post-operative period, and specific concomitant 
medications (i.e. fibrates, azoles, macrolides, cyclosporine, protease inhibitors, verapamil 
and amiodarone) (Pasternak et al., 2002).     
7. Toll-like receptor inhibitors 
7.1 Mechanism of action 
Key components of the innate immune system are pattern recognition receptors (PRRs), 
such as toll-like receptors (TLRs). These agents act as sentinels against damage-associated 
molecular pattern molecules (DAMPs), alarmins, and invading organisms carrying 
pathogen-associated molecular patterns (PAMPs) (Zhu & Mohan, 2010). PAMPs are a 
diverse set of microbial molecules which contain different recognizable biochemical 
features that alert the organism to intruding pathogens. Alarmins are non-infectious 
endogenous molecules that signal tissue and cell damage. Both alarmins and PAMPs are a 
subgroup of DAMPs (Bianchi, 2007). Once TLRs sense DAMPs, the innate immune 
response and antigen-specific adaptive immune response are activated. An intracellular 
cascade of signaling molecules occurs that ultimately activates the transcription factors, 
nuclear factor- κB (NF-κB) and interferon regulatory factors (IRFs). These transcription 
factors lead to expression of various inflammatory cytokines, interferons, and chemokines 
(Zhu & Mohan, 2010). 
There are at least 10 types of TLRs that have been identified in humans. Bacterial flagellin 
and Toxoplasma profilin are recognized by TLR5, TLR11 and TLR12. Bacterial lipopeptides 
are recognized by TLR1, TLR2 and TLR6. Lipopolysaccharide (LPS), found in the outer 
membrane of gram-negative bacteria, and endotoxin are recognized by TLR4 (Zhu & 
Mohan, 2010). Pharmacologic agents targeting individual TLRs are being developed in order 
to prevent activation of the immune response associated with DAMP binding. Of particular 
interest in sepsis are TLR2 and TLR4 because expression of these PRRs is increased on 
monocytes in healthy volunteers undergoing an LPS challenge (Wittbole et al., 2005), and in 
patients with sepsis (Harter et al., 2004).  
TLR4 binds with MD2, an extracellular accessory protein, which form a complex that 
interacts with LPS (Figure 4) (Wittebole, et al., 2010). Eritoran is a LPS antagonist that  
binds to the TLR4-MD-2 complex, rendering it unable to illicit the immune response. 
Resatorvid is another agent that inhibits TLR4 signaling by binding directly to a specific 
amino acid in the TLR4-intracellular domain, thus is a TRL4 antagonist (Wittebole,  
et al., 2010).  
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Other medications that are currently marketed for other indications have been found to 
interact with TLRs in animal studies. Agents such as chloroquine, ketamine, nicotine and 
statins have various immunologic properties through their interactions with TLRs 
(Wittebole, et al., 2010), but few studies exist to determine the clinical relevance of these 
interactions in humans. 
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LPS=Lipopolysaccharide, LBP=Lipopolysaccharide-binding protein, TLR-4=toll-like receptor 4, 
MD2=myb regulated gene, MyD88=myeloid differentiation primary response gene, IRAK-
1=interleukin-1 receptor associated kinase, TRAF-6=TNFa receptor associated factor, IkB=inhibitory 
kappa B proteins, NFkB=nuclear factor kappa B, DNA=deoxyribonucleic acid 
Fig. 4. Toll-like receptor 4 mechanism of action 
7.2 Pharmacology 
Eritoran has been studied as an intravenous infusion in a phase I study. Following 
administration, it has a relatively low volume of distribution and a long half-life, up to  
62.7 hours. Eritoran is highly bound to lipoproteins and is cleared hepatically (Rossignol  
et al., 2004). 
7.3 Clinical trials 
Of all of the agents that have TLR-modulating properties, eritoran has been studied the 
most extensively. In a laboratory study, eritoran caused a dose-dependent inhibitory 
effect on IL-6 and TNF-α production in LPS-stimulated human monocytes from healthy 
volunteers (Czeslick et al., 2006). Another group of healthy volunteers were challenged 
with 4 ng/kg of LPS. All eritoran doses, from 50 mcg to 250 mcg, achieved statistically 
significant reductions in elevated temperature, heart rate, C-reactive protein levels, white 
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blood cell count, TNF-α and IL-6 levels compared to placebo. In doses >100 mcg/kg, 
eritoran ameliorated LPS-induced fever, chills, headache, myalgia, and tachycardia (Lynn 
et al., 2003).  
A recent prospective, randomized, double-blind, placebo-controlled, multicenter, ascending-
dose phase II trial was conducted in 293 patients who were randomized either eritoran high 
dose (105 mg), eritoran small dose (45 mg) or placebo. A trend towards a lower mortality 
rate was observed in patients at highest risk of mortality by APACHE II score quartile in the 
eritoran 105 mg group. A trend toward a higher mortality rate was observed in subjects in 
the lowest APACHE II score quartile for the eritoran 105 mg group. Number of adverse 
events was similar among all treatment groups (Tidswell et al., 2010).  
A phase III study comparing eritoran 105 mg to placebo in patients with severe sepsis was 
conducted; however, due to fact that the study did not meet its primary endpoint of 
reduction of 28-day all-cause mortality Eisai Inc. will not submit marketing authorization 
applications. The pharmaceutical company will continue an analysis of the data and 
determine next steps. 
Resatorvid was studied in a randomized, double-blind, placebo-controlled study of patients 
with severe sepsis and related respiratory or cardiovascular failure. Unfortunately,  
this study was ended prematurely due to insufficient cytokine suppression (Wittebole et  
al., 2010).  
7.4 Place in therapy 
Though eritoran and resatorvid are not currently marketed and are still under investigation 
for use in severe sepsis and septic shock, pharmacologic agents targeting TLR2 and TLR4 
remain promising interventions. 
7.5 Adverse effects 
Eritoran was well tolerated in clinical trials. Anemia, diarrhea, insomnia, acute renal failure, 
phlebitis and rash were observed more frequently in the group receiving eritoran compared 
to the group receiving placebo. Serious adverse events included cardiac arrest, hepatobiliary 
events, multiorgan failure, sepsis, atrial fibrillation, respiratory failure and deep vein 
thrombosis (Tidswell et al., 2010). 
8. Conclusion 
Despite initiation of EGDT, severe sepsis and septic shock remain a major cause of mortality 
and economic burden in the United States. Each of the therapies discussed above can  
be considered after optimization of EGDT once the etiology and severity of sepsis is 
determined.  
Though the use of corticosteroid remains controversial, hydrocortisone can be considered in 
patients that are hemodynamically unstable despite adequate fluid resuscitation and 
vasopressor therapy. It is unclear at this time if there is a role for IVIG in all patients with 
severe sepsis and septic shock. Because IVIG neutralizes superantigens and opsonizes 
streptococci, patients with confirmed or suspected group GAS infections may benefit from 
therapy. Continuation of pre-existing statin therapy can be considered in patients with 
severe sepsis and septic shock with intact oral or enteral access. Finally, while there are 
currently no available toll-like receptor inhibitors marketed in the United States, 
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interventions at the cellular level in sepsis are still in their infancy of investigation and 
present promising adjunctive therapies.  
 
Drug Mechanism Dose Adverse Effects
Corticosteroids
Metabolic, 
cardiovascular, 
immunologic and anti-
inflammatory properties
Hydrocortisone 
200-300 mg/day 
divided in 3-4 
doses
Immune suppression, increased 
risk of infections, impaired 
wound healing, hyperglycemia, 
myopathies, hypokalemia, 
psychosis, HPA axis and GR 
suppression
Activated Protein C
Anticoagulant and pro-
fibrinolytic
24 mcg/kg/hr 
infusions for 96 
hours
Bleeding
IVIG
IgG antibodies; 
neutralize 
superantigens, opsonize
streptococci
Doses vary;
For STSS – 1 
g/kg on day 1, 0.5 
g/kg on day 2 &3
Headache, pyrexia, fatigue, 
rigors, nausea, chills, dizziness, 
vomiting, pain in extremity, 
urticaria, cough, hypersensitivity 
reactions, renal failure, aseptic 
meningitis
Statins
Immunologic, anti-
inflammatory, and 
anticoagulant properties 
Vary depending 
on agent (see 
table 2)
Myositis, rhabdomyolysis, 
elevated liver transaminases
TLR modulators
Direct or indirect TLR 
inihibition
Eritoran 105 mg 
intravenous
Anemia, diarrhea, insomnia, 
acute renal failure, phlebitis and 
rash, cardiac arrest,atrial
fibrillation, respiratory failure,
deep vein thrombosis
 
Table 3. Summary of Interventions 
Sepsis is a complex physiologic process that involves activation of the inflammatory system 
and coagulation cascade, thereby creating multiple outlets for possible therapeutic 
intervention. At this time, more research is warranted to determine the most optimal 
therapeutic regimen based on individual patient factors, such as etiology, severity of illness 
and comorbid conditions.   
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